Investors should monitor upcoming Q2 2026 data readouts from the REVEAL Phase 1/2 trial and completion of dosing in pivotal trials, which could serve as key catalysts for BLA submission. The expanded cash runway into 2028 reduces near-term dilution risk.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $4.56entry
- T+1 · 8mo ago −3.51%α −1.77% · $4.40
- T+5 · 8mo ago −5.26%α −3.05% · $4.32
- T+20 · 7mo ago +41.01%α +33.39% · $6.43
- T+60 · 5mo ago +30.92%α +16.58% · $5.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighting progress in its TSHA-102 program for Rett syndrome, including dosing in pivotal trials, FDA alignment on BLA-enabling strategies, and a favorable safety profile. Revenue increased to $9.77 million, though net loss widened to $109.0 million due to higher R&D and administrative expenses. The company has $319.8 million in cash, sufficient to fund operations into 2028.
Key Financial Metrics
Key Facts
- Revenue increased 17.3% YoY to $9.77 million in 2025
- Net loss widened to $109.0 million in 2025 from $89.3 million in 2024
- R&D expenses rose 30.9% to $86.4 million, driven by clinical trial and manufacturing costs
- Cash and cash equivalents totaled $319.8 million as of December 31, 2025
- FDA cleared initiation of ASPIRE trial and provided written alignment on CMC and BLA strategy
- No treatment-related SAEs or DLTs observed in REVEAL trials as of March 2026
- Dosing in REVEAL pivotal and ASPIRE trials on track for completion in Q2 2026
Financial Impact
Revenue grew 17.3% to $9.77 million, but net loss increased by $19.7 million due to higher R&D and G&A spending. Cash burn was significant, though offset by $50 million raised via ATM, leaving $319.8 million in cash.
Risk Factors
- Clinical development risk: TSHA-102 remains investigational with no guarantee of regulatory approval
- Cash burn remains high; future equity raises could lead to dilution despite current runway
- Revenue is minimal and non-recurring (likely from collaborations), not indicative of commercial product sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258910 |
Track record
14 reports on TSHA
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers